STATUS: Recruiting

SPONSOR: GINECO
LEAD GROUP: GINECO
ENGOT Model: A
TITLE: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus dostarlimab in first line advanced/metastatic setting.
ClinicalTrials.gov ID: NCT05201547
MaNGO sites (click to see the list)

STATUS: Recruiting

SPONSOR: Leiden University Medical Center
LEAD GROUP: DGOG
ENGOT Model: A
TITLE: A phase II study of tailored adjuvant therapy in Pole-mutated and p53-wildtype/NSMP early stage endometrial cancer (RAINBO BLUE & TAPER)
ClinicalTrials.gov ID: NCT05255653    
MaNGO sites (click to see the list)     

STATUS: Recruiting

SPONSOR: Karyopharm Therapeutics Inc.
LEAD GROUP: BGOG
ENGOT Model: C
TITLE: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
ClinicalTrials.gov ID: NCT05611931
MaNGO sites (click to see the list)

STATUS: Planned

SPONSOR: AGO Study Group
LEAD GROUP: AGO Study Group
ENGOT Model: A
TITLE: Evaluation of preoperative clinical and translation selection criteria for cytoreductive surgery in endometrial cancer . A retrospective multicenter trial with an accompanying translational Project. Surgical Treatment in Advanced and Recurrent Endometrial CAncer Management
ClinicalTrials.gov ID: to be defined
MaNGO sites (click to see the list)    

STATUS: Recruiting

SPONSOR: Merck Sharp & Dohme LLC
LEAD GROUP: MITO
ENGOT Model: C
TITLE: A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy
ClinicalTrials.gov ID:  NCT06132958
MaNGO sites (click to see the list) 

STATUS: Planned
SPONSOR: BioNTech SE

LEAD GROUP: NSGO
ENGOT Model: C
TITLE: A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent or metastatic endometrial cancer

ClinicalTrials.gov ID: NCT06340568

STATUS: Recruiting
SPONSOR: Gilead Sciences, Inc.

LEAD GROUP: MaNGO

ENGOT Model: C
TITLE: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy
ClinicalTrials.gov ID:  NCT06486441

MaNGO sites (click to see the list)